Jeffrey W. Jacobs Net Worth (2024) – wallmine.com (2024)

Last updated: 24 November 2021 at 4:50pm EST

The estimated Net Worth of Jeffrey W Jacobs is at least $1.13 Million dollars as of 22 November 2021. Mr Jacobs owns over 5,754 units of Ardelyx Inc stock worth over $771,860 and over the last 9 years he sold ARDX stock worth over $353,470.

Mr Jacobs ARDX stock SEC Form 4 insiders trading

Mr has made over 21 trades of the Ardelyx Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 5,754 units of ARDX stock worth $5,639 on 22 November 2021.

The largest trade he's ever made was selling 50,804 units of Ardelyx Inc stock on 15 September 2020 worth over $286,027. On average, Mr trades about 4,681 units every 96 days since 2015. As of 22 November 2021 he still owns at least 119,483 units of Ardelyx Inc stock.

You can see the complete history of Mr Jacobs stock trades at the bottom of the page.

Mr. Jeffrey W. Jacobs biography

Jeffrey W. Jacobs is the Chief Scientific Officer at Ardelyx Inc.

How old is Mr Jacobs?

Mr Jacobs is 57, he's been the Chief Scientific Officer of Ardelyx Inc since . There are 6 older and 11 younger executives at Ardelyx Inc. The oldest executive at Ardelyx Inc is GordonRingold, 69, who is the Independent Director.

What's Mr Jacobs's mailing address?

Jeffrey's mailing address filed with the SEC is C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT, CA, 94555.

Insiders trading at Ardelyx Inc

Over the last 10 years, insiders at Ardelyx Inc have traded over $36,333,517 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871. The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence.On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $2,119,415. The most recent stock trade was executed by Laura A Williams on 5 June 2024, trading 145,000 units of ARDX stock currently worth $1,032,400.

What does Ardelyx Inc do?

ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.

What does Ardelyx Inc's logo look like?

Ardelyx Inc executives and stock owners

Ardelyx Inc executives and other stock owners filed with the SEC include:

• MichaelRaab,
  President, Chief Executive Officer, Director
• Michael G. Raab,
  Pres, CEO & Director
• DavidRosenbaum,
  Chief Development Officer
• ElizabethGrammer,
  Chief Legal and Administrative Officer
• Susan Rodriguez,
  Chief Commercial Officer
• Justin A. Renz CPA, MST, M.S.T., MBA,
  CFO & Chief Accounting Officer
• GeoffreyBlock,
  Independent Director
• DavidMott,
  Independent Chairman of the Board
• RichardRodgers,
  Independent Director
• GordonRingold,
  Independent Director
• WilliamBertrand,
  Independent Director
• JanLundberg,
  Independent Director
• RobertBazemore,
  Independent Director
• OnaizaCadoret-Manier,
  Independent Director
• SusanRodriguez,
  Chief Commercial Officer
• JustinRenz,
  Chief Accounting and Principal Financial Officer
• Dr. Laura A. Williams M.D., M.P.H.,
  Chief Medical Officer
• Dan Pavicich,
  Sr. Director of Market Devel.
• David P. Rosenbaum,
  Chief Devel. Officer
• Elizabeth A. Grammer,
  Chief Legal & Admin. Officer and Sec.
• Karen Harrigan,
  Sr. Director Market Devel.
• Robert C. Blanks,
  Chief Regulatory Affairs & Quality Assurance Officer
• Sarah O'Brien,
  Chief People Officer
• Kimia Keshtbod,
  Mang. of Corp. Communications & Investor Relations
• Jeffrey W. Jacobs,
  Chief Scientific Officer
• Peter W. Sonsini,
  10% owner
• Jon Sakoda,
  10% owner
• Patrick J Kerins,
  10% owner
• 15 Gp, Llc Nea,
  10% owner
• Jeremy S Caldwell,
  EVP, Chief Scientific Officer
• Mark Kaufmann,
  Chief Financial Officer
• Harry R Weller,
  10% owner
• Ravi Viswanathan,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Peter J Barris,
  10% owner
• Reginald Seeto,
  Chief Operating Officer
• Scott D Sandell,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Enterprise Associates 12, L...,
  
• Annalisa Jenkins,
  Director
• Paul Korner,
  EVP, Chief Medical Officer
• Joshua Makower,
  10% owner
• Forest Baskett,
  10% owner
• M James Barrett,
  10% owner
• Enterprise Associates 12, L...,
  10% owner
• Partners 12, Limited Partne...,
  
• Mohamad Makhzoumi,
  10% owner
• Muna Bhanji,
  Director
• Mike Kelliher,
  See Remarks
• Narani Arasaratnam,
  VP, Corporate Controller
• Ventures Vii Lpcmea Venture...,
  
• Peter G Schultz,
  Director
• Ryan D Drant,
  10% owner
• George Jue,
  VP, Operations & Facilities
• Partners 12, Limited Partne...,
  
• Jeffrey W Jacobs,
  Chief Scientific Officer
• Robert Ora Felsch,
  See Remarks
• Robert Blanks,
  See Remarks
• Laura A Williams,
  Chief Medical Officer